WuXi PharmaTech (WX) Tops Q3 EPS by 6c; Boosts FY12 Outlook, Guides Q4
Tweet
Share
E-mailGet Alerts WX Hot Sheet
Join SI Premium – FREE
WuXi PharmaTech (NYSE: WX) reported Q3 EPS of $0.36, $0.06 better than the analyst estimate of $0.30. Revenue for the quarter came in at $125.8 million versus the consensus estimate of $123.04 million.
WuXi PharmaTech sees FY2012 revenue of $495-498 million, versus prior guidance of $488-498 million and the consensus of $485.0 million.
WuXi PharmaTech sees Q4 2012 revenue of $121-124 million, versus the consensus of $119.73 million.
For earnings history and earnings-related data on WuXi PharmaTech (WX) click here.
WuXi PharmaTech sees FY2012 revenue of $495-498 million, versus prior guidance of $488-498 million and the consensus of $485.0 million.
WuXi PharmaTech sees Q4 2012 revenue of $121-124 million, versus the consensus of $119.73 million.
For earnings history and earnings-related data on WuXi PharmaTech (WX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
